Avaí Bio and Austrianova have completed a GMP master cell bank for an early-stage α-Klotho cell therapy program.
Avaí Bio and Austrianova have completed a good manufacturing practice (GMP) master cell bank (MCB) of genetically modified cells designed to overexpress the α-Klotho protein, moving the companies’ early-stage cell-based program toward additional release testing rather than clinical evaluation. The companies said the bank will now undergo independent testing for pathogenic viruses and adventitious agents before the generation of a working cell bank for the manufacture of a planned encapsulated clinical product (Cell-in-a-Box).1
“We are pleased that this first step in the production phase of α-Klotho producing cells has been successfully completed,” Chris Winter, CEO of Avaí Bio, said in a company press release.1
The update is primarily a chemistry, manufacturing, and controls milestone. No investigational new drug (IND) application, clinical trial authorization, patient dosing, or efficacy data were reported. For a cell therapy based on genetically modified cells, however, establishment of a qualified cell bank is a foundational step because it defines the starting material used to produce subsequent lots and supports consistency, traceability, and contamination control.
According to Avaí Bio, the MCB consists of a homogeneous collection of vials derived from a single clone and produced under GMP standards. The companies said the next testing phase is intended to confirm the absence of pathogenic viruses and to assess for bacteria, mycoplasma, fungi, yeast, and other adventitious agents through an accredited third-party provider independent of Avaí Bio, Austrianova, and their joint venture, Klothonova.1 If the MCB passes testing, α-Klotho–overexpressing cells from the bank would be used to create a working cell bank, which would then supply cells for encapsulated product manufacturing.
FDA guidance for human gene therapy IND applications emphasizes detailed characterization of cellular starting materials, vector-related components, cell substrates, manufacturing controls, and assays for identity, purity, potency, and adventitious agents.2 Although the companies cited FDA regulatory expectations, they did not state whether they have requested FDA feedback, submitted a pre-IND package, or defined a first-in-human trial protocol.
The therapeutic rationale centers on α-Klotho, a protein implicated in aging biology, phosphate homeostasis, kidney physiology, vascular health, and other pathways. Interest in Klotho increased after a landmark animal study reported that disruption of the klotho gene in mice produced a syndrome resembling accelerated aging.3 Since then, Klotho has been studied in relation to kidney disease, neurodegeneration, vascular calcification, and metabolic dysfunction, but translation into approved human therapeutics remains unproven.
Avaí Bio and Austrianova are positioning the program for age-related disorders and anti-aging applications, including kidney disease, neurodegenerative disorders, and vascular diseases.1 Clinically, those conditions are heterogeneous indications with different biology, endpoints, and regulatory expectations. Chronic kidney disease, for example, is managed through risk-factor modification, blood pressure control, renin-angiotensin system blockade when appropriate, sodium-glucose cotransporter 2 inhibitors in eligible patients, and disease-specific interventions, yet many patients remain at risk for progression and cardiovascular complications.4 Demonstrating that sustained α-Klotho delivery can alter clinically meaningful outcomes would require indication-specific trials rather than biomarker rationale alone.
Austrianova’s Cell-in-a-Box platform represents an encapsulation approach intended to contain living cells while permitting secretion of therapeutic proteins.
The companies’ joint venture, Klothonova, was established in September 2025 as a Nevada-based company equally owned by Avaí Bio and Austrianova affiliate SG Austria. The joint venture is focused on sustainable production of α-Klotho through encapsulated cell-based therapies.1 Austrianova had previously completed production of the α-Klotho–expressing cells for Klothonova and would proceed toward production of encapsulated clinical product for patient application, according to
The main implication for biopharmaceutical development lies in the program advancing from cell-line generation into GMP banking and release testing. That transition can reduce manufacturing variability if the bank is adequately characterized, but it does not establish clinical activity.
This milestone is a step toward clinical readiness rather than evidence of therapeutic benefit. The next meaningful disclosures would include completion of viral and adventitious-agent testing, working cell bank qualification, preclinical pharmacology and toxicology data, regulatory interactions, and a defined clinical development plan with measurable endpoints.
